University of Zurich: Glioblastoma trials

The registry lists 10 Glioblastoma studies with University of Zurich as lead sponsor. 4 are open to participants now and 0 have results posted.

Phase 1 2Phase 2 8No phase 2(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Vortioxetine for Newly Diagnosed GlioblastomaRecruitingNCT07284628Phase 2
• Pharmacoscopy for Patients With Refractory Primary Brain TumorsRecruitingNCT06804655Phase 2
• Glutamate Inhibitors in GlioblastomaRecruitingNCT05664464Phase 1/2
• Response Assessment During MR-guided Radiation Therapy for GlioblastomaRecruitingNCT05565326
• Pembrolizumab for Newly Diagnosed GlioblastomaActive, not recruitingNCT03899857Phase 2
• Avastin Plus Radiotherapy in Elderly Patients With GlioblastomaCompletedNCT01443676Phase 2
• Combined Approach to Resection of Glioblastoma (GBM) by 5-Aminolevulinic Acid (5-ALA) and Intraoperative Magnetic Resonance Imaging (MRI)Status unknownNCT01208909
• Patupilone (EPO 906) in Patients With Recurrent or Progressive GlioblastomaCompletedNCT00715013Phase 1/2
• Temozolomide vs. Temozolomide and Thalidomide Treatment in Recurrent GlioblastomaStatus unknownNCT00521482Phase 2
• Pre- and Postoperative Use of ZD1839 (Iressa) in Recurrent Glioblastoma, Including Translational ResearchCompletedNCT00250887Phase 2